Skip to main content

Remote Job Finders (RJF)

From Weight Loss to Hair Loss: The Search for the Next Blockbuster

A new generation of companies is eyeing the existing, sizeable hair loss market, hoping that better formulations and new scientific targets will finally produce treatments that are safer and more effective, as well as commercially successful.

Novo CEO Fires Back at Pfizer From White House: ‘Put Your Hand in Your Pocket’

During a press conference to announce a drug price deal for GLP-1s, President Donald Trump asked for more details about the ongoing bidding war between Novo Nordisk and Pfizer over obesity biotech Metsera.

The GLP-1 Paradox—Why Is a $95B Obesity Market Ignoring Its Biggest Problem?

The nausea and other gastrointestinal side effects of weight loss drugs like Novo Nordisk’s Wegovy or Eli Lilly’s Zepbound will limit how much these drugs can help patients and stunt the overall obesity market unless we approach the problem head on.

Novo’s Metsera Bid Attracts FTC Scrutiny as Pfizer Matches $10B Offer

Pressure from the FTC and Pfizer is building around Novo Nordisk’s bid to snatch obesity biotech Metsera. The antitrust watchdog has spotted issues with the structure of Novo’s bid, while its New York-based rival has put more money on the table.
Scroll to top